STAGE II BREAST CANCER AJCC V6 AND V7
Clinical trials for STAGE II BREAST CANCER AJCC V6 AND V7 explained in plain language.
Never miss a new study
Get alerted when new STAGE II BREAST CANCER AJCC V6 AND V7 trials appear
Sign up with your email to follow new studies for STAGE II BREAST CANCER AJCC V6 AND V7, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for tough breast cancer: drug cocktail shrinks tumors before surgery
Disease control CompletedThis study tested a combination of three drugs (panitumumab, carboplatin, and paclitaxel) given before surgery to women with triple-negative breast cancer whose tumors did not respond to standard chemotherapy. The goal was to shrink the tumor enough to remove less breast tissue. …
Matched conditions: STAGE II BREAST CANCER AJCC V6 AND V7
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 07:10 UTC
-
Smart pill bottles and video chats boost breast cancer treatment adherence
Disease control CompletedThis study tested whether using telehealth (video chats with doctors) and smart pill bottles can help breast cancer patients take their hormone therapy pills more consistently. About 305 women and men with early-stage hormone-sensitive breast cancer took part. The goal was to see…
Matched conditions: STAGE II BREAST CANCER AJCC V6 AND V7
Phase: NA • Sponsor: Thomas Jefferson University • Aim: Disease control
Last updated May 17, 2026 06:48 UTC
-
New combo shrinks hard-to-treat breast tumors before surgery
Disease control CompletedThis study tested a combination of enzalutamide (a hormone blocker) and paclitaxel (chemotherapy) given before surgery to people with a specific type of triple-negative breast cancer that has androgen receptors. The goal was to see if this treatment could shrink tumors and reduce…
Matched conditions: STAGE II BREAST CANCER AJCC V6 AND V7
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 13, 2026 16:02 UTC
-
New combo therapy shows promise in preventing breast cancer return
Disease control CompletedThis study tested a combination of chemotherapy drugs (cyclophosphamide and paclitaxel) plus the targeted therapy trastuzumab given after surgery to 20 patients with early-stage HER2-positive breast cancer. The goal was to see how safe and effective this treatment is at preventin…
Matched conditions: STAGE II BREAST CANCER AJCC V6 AND V7
Phase: PHASE2 • Sponsor: University of Nebraska • Aim: Disease control
Last updated May 11, 2026 20:46 UTC